slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,539
Current window 92,791-92,820
Pages 3,685
Rows per page 30
Component
92,791-92,820 of 110,539
03
The slide outlines the status of THIO-101, 102, and 103, highlighting FDA designations and clinical trial progress.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · The Ask1 hit
08
The slide illustrates a sequential therapeutic approach: THIO treatment followed by CPI therapy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
10
The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
13
Data cut of ongoing study THIO-101 as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
14
The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
16
The chart tracks individual patient timelines, including disease progression, partial responses, and study outcomes.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
18
The slide presents two line charts showing tumor volume reduction over time, highlighting 100% complete response (CR) and resistance to tumor rechallenge.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The slide presents two line charts showing tumor volume over time, illustrating the efficacy of THIO in primary treatment and rechallenge scenarios.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Competition1 hit
03
The slide uses a 2x3 grid layout to present key company pillars.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a visual timeline/process flow to show disease progression.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
The slide uses a two-part framework: Targeting (left) and Delivery (right).Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
09
The slide uses a process flow diagram to map clinical outcomes to specific trial metrics.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
21
The chart shows dose-response curves where LNC formulations consistently outperform Taxol.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
22
The slide uses a timeline diagram to explain the experimental design and a line chart to show tumor volume reduction over time.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
25
Includes study design details (n=55, female C57BL/6 mice) and statistical significance markers for treatment groups.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
28
The slide uses a grid layout to display headshots and names for the executive team, and a list format for the board of directors with associated company logos.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
04
Includes a specific note regarding the effective income tax rate increase.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
05
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
06
Matson | Results Presentation Deck | 10 slidesMatson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
07
The chart compares quarterly container volumes between 2022 and 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
08
The chart compares 2022 vs 2023 quarterly container volumes.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
09
The chart shows quarterly container volume (FEU) for 2022 vs 2023.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
10
The chart shows quarterly operating income for 2022 and 2023, with Q4 2023 highlighted as a range.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · Satisfaction1 hit
04
The slide uses a dual-track timeline (Cell Therapy and Drug Discovery) to show company evolution.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
08
The chart shows a cumulative growth trend of partner milestones over time, with logos placed in vertical columns representing years.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit